Octapharma AG

Activities: Manufacturing Pharmaceutical

Trending Articles

  1. IMPACT CKD model reveals the escalating toll of chronic kidney disease The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  3. Isospec Analytics launches biomolecular analysis technology to identify unknown molecules The novel technology optimises the identification process of unknown molecules compared to mass analysis
  4. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
  5. ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

New NCEs focus on cancer and orphan diseases

The number of NCEs approved in Europe increased again in 2014, with the spotlight on cancer drugs and treatments for unmet medical needs. Dr Sarah Houlton reviews the new entrants
Research & Development

Octapharma opens €25m recombinant research facility

Provides a laboratory and office space for up to 120 people in Heidelberg
Ingredients

BAC and Octapharma expand G-CSF ligand collaboration

BAC and Octapharma extend G-CSF custom ligand collaboration for commercial scale manufacture
Research & Development

BAC and Octapharma extend recombinant Factor IX collaboration

<p>BAC, a Dutch provider of antibody-based affinity purification technology, has signed a licence agreement with Octapharma, a Swiss biopharmaceutical company, to use BAC's anti-Factor IX CaptureSelect affinity ligand in the large-scale purification of recombinant Factor IX (FIX). </p>
Manufacturing

Fresenius Kabi and Octapharma sign licensing agreement

<p>Fresenius Kabi of Germany and Swiss biopharmaceutical company Octapharma Group have signed a licensing agreement regarding the use of Fresenius Kabi\'s HESylation technology to develop a HESylated recombinant protein. </p>
Subscribe now